The development of genetic methods has led to the identification of molecular ALL subgroups, such as BCR/ABL1 chromosomal aberration, with pronounced biological and clinical features associated with poor results of treatment [9,10]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.